Key result
Recombinant human thrombomodulin achieves ~77% 28-day survival in post-surgical DIC, with early use linked to lower mortality.
Why the study?
Does recombinant human thrombomodulin improve survival and coagulation parameters safely in patients with DIC complicating cardiovascular surgery?
Observational (n=35)
No
Does recombinant human thrombomodulin improve survival and coagulation parameters safely in patients with DIC complicating cardiovascular surgery?
Recombinant human thrombomodulin appears safe and may improve coagulation parameters and survival in patients with DIC complicating cardiovascular surgery.
TM appeared safe with DIC parameter gains in survivors; leaves open efficacy confirmation in randomized CV surgery trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Koike et al. (2013) conducted an observational in Disseminated intravascular coagulopathy (DIC) after cardiovascular surgery (n=35). Recombinant human soluble thrombomodulin (rhsTM) vs. Delayed administration (historical comparison) was evaluated on 28-day survival. In patients with DIC after cardiovascular surgery, treatment with recombinant human soluble thrombomodulin resulted in a 77.1% 28-day survival rate, with early administration significantly reducing mortality compared to delayed treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: